Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with connective tissue diseases

The explosive growth of medical literature on pulmonary hypertension (PH) has led to a steady increase in awareness of this disease within the medical community during the past decade. The recent revision of the classification of PH is presented in in the main guidelines. Group 1 PH or pulmonary arterial hypertension (PAH) is a heterogeneous group and includes PH due to inheritable, drug-induced, and toxin-induced causes and to such underlying systemic causes as connective tissue diseases, human immunodeficiency viral infection, portal hypertension, congenital heart disease, and schistosomiasis. Systemic sclerosis (SSc) is an autoimmune multisystem disorder, which affects over 240 persons per million in the United States.[1] Its manifestations are not confined to the skin but may also involve the lungs, kidneys, peripheral circulation, musculoskeletal system, gastrointestinal tract, and heart. The outcome of PAH associated with SSc is worse when compared to other subtypes of PAH. In this review, we summarize available information about the pulmonary vascular and cardiac manifestations of SSc with special emphasis on their prognostic implications as well as the peculiarity of their detection.

• Publication year

  2014

• Venue

  Annals of Thoracic Medicine

• Publication date

  2014-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.4103/1817-1737.134016PMID 25076994PMCID 4114266
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pulmonary hypertension: Another light in the dark tunnel. Learning the lesson from cancer

  2013cited by this paper
• Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study

  2013cited by this paper
• Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.

  2010cited by this paper
• Systemic sclerosis and bilateral lung transplantation: a single centre experience

  2010cited by this paper
• Ventricular mass index correlates with pulmonary artery pressure and predicts survival in suspected systemic sclerosis-associated pulmonary arterial hypertension.

  2009cited by this paper
• High N-Terminal Pro–Brain Natriuretic Peptide Levels and Low Diffusing Capacity for Carbon Monoxide as Independent Predictors of the Occurrence of Precapillary Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis

  2009cited by this paper
• Tadalafil Therapy for Pulmonary Arterial Hypertension

  2009cited by this paper
• Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension

  2009cited by this paper
• Longterm Survival Among Patients with Scleroderma-associated Pulmonary Arterial Hypertension Treated with Intravenous Epoprostenol

  2009cited by this paper
• Evaluation of recently validated non-invasive formula using basic lung functions as new screening tool for pulmonary hypertension in idiopathic pulmonary fibrosis patients

  2009cited by this paper
• Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension.

  2009cited by this paper
• Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era.

  2009cited by this paper
• An update in pulmonary hypertension in systemic lupus erythematosus – do we need to know about it?

  2008influential reference
• Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2

  2008cited by this paper
• Identification of candidate genes in scleroderma-related pulmonary arterial hypertension.

  2008cited by this paper
• Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: A controlled study of 100 consecutive patients.

  2008cited by this paper
• Ambrisentan for the Treatment of Pulmonary Arterial Hypertension

  2008cited by this paper
• Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension.

  2008cited by this paper
• High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.

  2008cited by this paper
• Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension

  2008cited by this paper
• Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.

  2008cited by this paper
• Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.

  2008cited by this paper
• The associations between tricuspid annular plane systolic excursion (TAPSE), ventricular dyssynchrony, and ventricular interaction in heart failure patients.

  2008cited by this paper
• Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension.

  2008cited by this paper
• Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension

  2007cited by this paper
• Right Ventricular Tissue Doppler and Strain Imaging: Ready for Clinical Use?

  2007cited by this paper
• Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.

  2007cited by this paper
• Pulmonary Arterial Hypertension: A Rare Complication of Primary Sjögren Syndrome: Report of 9 New Cases and Review of the Literature

  2007cited by this paper
• Changes in causes of death in systemic sclerosis, 1972–2002

  2007cited by this paper
• An epidemiological study of pulmonary arterial hypertension

  2007cited by this paper
• Cardiac magnetic resonance imaging detects subclinical right ventricular impairment in systemic sclerosis.

  2007cited by this paper
• Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension

  2007cited by this paper
• Right ventricle Tei-index: a tool to increase the accuracy of non-invasive detection of pulmonary arterial hypertension in connective tissue diseases.

  2007influential reference
• Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases.

  2007influential reference
• Right Heart Function and Scleroderma: Insights from Tricuspid Annular Plane Systolic Excursion

  2007cited by this paper
• Vascular complications of scleroderma.

  2007cited by this paper
• Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients

  2007cited by this paper
• Tricuspid annular displacement predicts survival in pulmonary hypertension.

  2006cited by this paper
• Right heart function in scleroderma: insights from myocardial Doppler tissue imaging.

  2006cited by this paper
• Clinical differences between idiopathic and scleroderma-related pulmonary hypertension.

  2006influential reference
• Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension.

  2006cited by this paper
• Treatment of pulmonary arterial hypertension.

  2006cited by this paper
• Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension.

  2006influential reference
• Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial.

  2006cited by this paper
• Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions

  2006cited by this paper
• Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension

  2006cited by this paper
• Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure.

  2006cited by this paper
• Pulmonary arterial hypertension in France: results from a national registry.

  2006cited by this paper
• Survival in patients with pulmonary arterial hypertension treated with first‐line bosentan

  2006cited by this paper
• Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.

  2006influential reference
• Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.

  2006cited by this paper
• Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension.

  2006cited by this paper
• Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma.

  2006cited by this paper
• Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers

  2006cited by this paper
• Sildenafil citrate therapy for pulmonary arterial hypertension.

  2005cited by this paper
• Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension

  2005cited by this paper
• Lessons learned from cancer may help in the treatment of pulmonary hypertension.

  2005cited by this paper
• Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension

  2005cited by this paper
• The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study).

  2005cited by this paper
• Autoimmunity and pulmonary hypertension: a perspective

  2005cited by this paper
• Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.

  2005cited by this paper
• The -2518 promotor polymorphism in the MCP-1 gene is associated with systemic sclerosis.

  2005cited by this paper
• -238 and +489 TNF-alpha along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with Systemic Sclerosis.

  2005cited by this paper
• Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study.

  2005cited by this paper
• The right ventricle in pulmonary hypertension

  2005cited by this paper
• Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.

  2005cited by this paper
• Systemic sclerosis associated pulmonary hypertension: improved survival in the current era

  2005cited by this paper
• Reversal of experimental pulmonary hypertension by PDGF inhibition.

  2005cited by this paper
• Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension

  2004influential reference
• A study of the prevalence of systemic sclerosis in northeast England.

  2004cited by this paper
• Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis.

  2004cited by this paper
• Following the Molecular Pathways toward an Understanding of the Pathogenesis of Systemic Sclerosis

  2004cited by this paper
• High prevalence of right ventricular systolic dysfunction in early systemic sclerosis.

  2004cited by this paper
• Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension

  2004influential reference
• [Pulmonary hypertension associated with systemic lupus erythematosus].

  2004cited by this paper
• Genetic basis of pulmonary arterial hypertension: current understanding and future directions.

  2004influential reference
• Endothelial Dysfunction in Pulmonary Hypertension

  2004cited by this paper
• Epidemiological study of patients with systemic sclerosis in Tokyo

  2004cited by this paper
• Interleukin 1alpha single-nucleotide polymorphism associated with systemic sclerosis.

  2004cited by this paper
• Treatment of pulmonary arterial hypertension.

  2004cited by this paper
• Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement.

  2003cited by this paper
• Systemic sclerosis: the susceptible host (genetics and environment).

  2003cited by this paper
• Association of IL1A gene polymorphisms with susceptibility to and severity of systemic sclerosis in the Japanese population.

  2003cited by this paper
• Age and risk of pulmonary arterial hypertension in scleroderma.

  2003cited by this paper
• Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence.

  2003cited by this paper
• Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis.

  2003cited by this paper
• Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach

  2003cited by this paper
• Elevated vascular endothelial growth factor in systemic sclerosis.

  2003cited by this paper
• Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis.

  2003cited by this paper
• Analysis of the 5' flanking region of the interleukin 10 gene in patients with systemic sclerosis.

  2003cited by this paper
• Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population.

  2003cited by this paper
• Scleroderma epidemiology.

  2003influential reference
• Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers

  2002cited by this paper
• Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy

  2002cited by this paper
• Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

  2002cited by this paper
• BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION

  2002cited by this paper
• Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases.

  2002cited by this paper
• Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis.

  2002cited by this paper
• Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations.

  2002cited by this paper
• Bosentan therapy for pulmonary arterial hypertension.

  2002cited by this paper

• The disproportionate burden of pulmonary arterial hypertension among the elderly: global, regional, and national trends from 1990 to 2021—findings from the 2021 global burden of disease study

  2025cites this paper
• Anxiety and Depression in Patients with Pulmonary Hypertension and its Impact on Health-Related Quality of Life

  2021cites this paper
• Pulmonary hypertension in the developing world: Local registries, challenges, and ways to move forward

  2020cites this paper
• Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study

  2019cites this paper
• The Saudi Thoracic Society pneumococcal vaccination guidelines-2016

  2016cites this paper
• The Saudi Initiative for Asthma - 2016 update: Guidelines for the diagnosis and management of asthma in adults and children

  2016cites this paper